Insmed INSM Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 81.8%+5.3pp | 79.7%+3.3pp | 76.5%-0.7pp | 75.7%-1.9pp | 76.5%-1.6pp | |
| Operating margin | -140.6%+117pp | -205.6%+35.9pp | -258.9%-18.0pp | -252.4%-21.0pp | -257.4%-33.3pp | |
| Net margin | -144.4%+121pp | -210.5%+40.7pp | -264.8%-12.8pp | -259.8%-15.5pp | -265.9%-29.2pp | |
| EBITDA margin | -138.3%+116pp | -202.9%+35.6pp | -255.9%-17.8pp | -249.3%-20.4pp | -254.5%-32.6pp | |
| Free cash flow margin | -112.5%+94.7pp | -159.6%+34.5pp | -202.7%-17.3pp | -218.2%-38.4pp | -207.1%-20.6pp | |
| Returns | ||||||
| Return on equity | -294.5%— | -249.3%— | -165.7%— | -160.5%— | —— | |
| Return on assets | -61%+7.4pp | -59.5%-5.1pp | -53.6%-2.5pp | -48.2%+1.2pp | -68.4%-12.6pp | |
| Return on invested capital | -149.4%+48.9pp | -146.6%-8.5pp | -104.8%+9.7pp | -365.2%-10.2pp | -198.3%+242pp | |
| Efficiency | ||||||
| Asset turnover | 0.4×+0.2× | 0.3×+0.1× | 0.2×0.0× | 0.2×0.0× | 0.3×0.0× | |
| Inventory turnover | 1.3×+0.3× | 1.1×+0.1× | 1×+0.1× | 1×+0.1× | 1×+0.1× | |
| Liquidity | ||||||
| Current ratio | 4.5×-1.4× | 3.8×-1.6× | 4.6×-1.7× | 6.7×+4.0× | 5.9×+4.1× | |
| Quick ratio | 4.1×-1.3× | 3.5×-1.6× | 4.3×-1.6× | 6.3×+3.8× | 5.4×+3.8× | |
| Cash ratio | 1.6×-0.1× | 1.1×-0.8× | 0.8×-1.0× | 4.1×+1.7× | 1.7×+0.3× | |
| Leverage | ||||||
| Debt-to-equity | 0.8×-10.7× | 0.8×-3.2× | 0.6×-1.5× | 0.5×-30.9× | 11.5×— | |
| Debt-to-assets | 0.3×-0.4× | 0.3×-0.3× | 0.2×-0.2× | 0.2×-0.4× | 0.6×-0.4× | |
| Interest coverage | -14×-2.5× | -14.9×-4.5× | -13.7×-3.8× | -11.8×-2.6× | -11.5×-2.9× | |
| Per Share | ||||||
| Book value per share | $3.27+497% | $3.71+113% | $4.47+60.5% | $6.60+2,531% | $0.55+118% | |
| Valuation | ||||||
| Market capitalization | $35.25B+155% | $37.12B+201% | $30.44B+170% | $20.12B+102% | $13.81B+251% | |
| Enterprise value | $35.25B+142% | $37.2B+187% | $30.68B+159% | $19.41B+95.7% | $14.55B+220% | |
| Price / sales | 43×+6.8× | 61.2×+27.2× | 68.1×+35.2× | 50.5×+20.3× | 36.2×+23.8× | |
| Price / book | 50×-89.2× | 50.2×+6.9× | 32.2×+8.8× | 16.1×-240× | 139.3×— | |
| EV / sales | 43×+4.8× | 61.3×+25.7× | 68.6×+34.1× | 48.7×+18.6× | 38.2×+23.8× | |
| Free cash flow yield | -2.6%+3.1pp | -2.6%+3.1pp | -3%+2.7pp | -4.3%+1.6pp | -5.7%+9.3pp | |
| Earnings yield | -3.4%+4.0pp | -3.4%+4.0pp | -3.9%+3.8pp | -5.1%+2.9pp | -7.3%+11.7pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Insmed's profit margins?
- Insmed (INSM) runs a 81.8% gross margin and a -140.6% operating margin, with a -144.4% net margin.
- Where do Insmed's ratios come from?
- Every ratio is computed from Insmed's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
